Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2002

View Archived Issues

Novel diazoxide analogue preserves beta-cell function

TLK-19780, a nonpeptide insulin receptor activator

Glucose concentration-dependent insulin secretion potentiators identified at Kyowo Hakko

AndroGel continues to provide benefits in hypogonadal men for up to 42 months

MMP-targeting NeuGene antisense agent inhibits prostate cancer growth

Selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor effective in type 2 diabetes model

GW-3965, a synthetic LXR ligand, displays potent antiatherogenic activity

Antiinflammatory activity of IS-741 in experimental colitis

Australia first to approve Xolair

Potent in vitro activity of ravuconazole and voriconazole against Candida spp.

Inflazyme reports on development of key LSAIDs

Cytovax updates progress of key product candidates

Synthesis and therapeutic applications of glucocorticoid receptor modulators

Plexus Vaccine establishes subsidiary for new vaccine development

Celgene and Novartis advance SERM osteoporosis program

Genelabs permitted to seek E.U. approval for Aslera under centralized procedure

Tanox outlicenses Bak gene

Xenerex awarded funding for development of anthrax therapy

UCB presents R&D overview

New agents for HIV identified at Parker Hughes Institute

Recent patent covers new PDE5 inhibitors designed at Lilly Icos

Novartis presents new PKC inhibitors and use in autoimmune diseases, cancer, etc.

Pyrimidine NPY receptor antagonists useful for obesity

Calcilytic compounds in development at GSK for osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...